Review

For reprint orders, please contact reprints@expert-reviews.com

Challenging hypertension: how to diagnose and treat resistant hypertension in daily clinical practice
Expert Rev. Cardiovasc. Ther. 8(6), 811820 (2010)

Massimo Volpe1,2 and Giuliano Tocci1

Division of Cardiology, II Faculty of Medicine, University of Rome La Sapienza, SantAndrea Hospital, ViadiGrottarossa, 1035-9, 00189Rome, Italy 2 IRCCS Neuromed, Pozzilli (IS), Italy Author for correspondence: Tel.: +39 063 377 5654 Fax: +39 063 377 5061 massimo.volpe@uniroma1.it
1

Arterial hypertension is a very complex disease characterized by a sustained rise in systolic and/or diastolic blood pressure (BP) levels and a significantly increased risk of developing major adverse cardiovascular and renal outcomes. Although BP-lowering treatment reduces the hypertensionrelated burden of disease, BP control continues to be poorly achieved worldwide. A major factor contributing to this therapeutic failure is represented by resistant (or refractory) hypertension. The diagnosis of resistant hypertension is very common in clinical practice, yet it is often used to improperly define patients with difficult or challenging forms of hypertension. An incorrect use of this definition by physicians may lead to clinical behaviors that do not help to improve BP control; on the other hand, correct diagnosis of resistant hypertension may facilitate the successful treatment of hypertension. In this article, we will review and discuss the definition, pathophysiological mechanisms, diagnostic algorithms and potential new therapeutic options for treating resistant hypertension.
Keywords : antihypertensive treatment blood pressure control clinical inertia refractory hypertension
resistant hypertension

Blood pressure control in the hypertensive population: focus on resistant hypertension

Arterial hypertension is a very complex disease[1] . Its pathophysiology is characterized by the intervention of multiple factors, leading to a substantial and persistent increase in blood pressure (BP) levels, and higher susceptibility to develop organ damage and overt cardio vascular (CV) and renal complications, including myocardial infarction, stroke, heart failure and end-stage renal disease [2] . BP reduction is, in turn, parallel ed by marked reductions in fatal and nonfatal outcomes in hypertensive patients with different degrees of global CV risk profile [3,4] . In spite of the progressive and considerable improvements achieved in diagnostic options and therapeutic interventions, recent observational surveys continue to show persistently low rates of BP control in the general population of hypertensive patients [5] . The treatment of hypertension, in fact, usually requires a therapeutic approach based on the adherence to
www.expert-reviews.com 10.1586/ERC.10.47

healthy lifestyle measures and use of antihypertensive drugs[68] . In approximately two-thirds of hypertensive patients, however, a combination therapy based on the association of multiple agents belonging to different antihypertensive drug classes is required [9,10] . Of note, even with the most updated therapeutic approach based on the use of lifestyle measures and combination drug strategies, BP levels remain elevated in the majority of patients [11] . Numerous patients with poor BP control in clinical practice are improperly classified as having resistant hypertension. This diagnosis is not always appropriate and often misused to define patients with difficult-to-treat or challenging forms of hypertension [12,13] . A difficult control of BP levels in hypertensive patients may, indeed, be related to several factors, including doctors inertia, patients poor compliance, insufficient patientdoctor communication, inappropriate BP measurements, or inadequate or insufficient antihypertensive interventions. These conditions obviously do not represent true resistant hypertension. They
ISSN 1477-9072

2010 Expert Reviews Ltd

811

Review

Volpe & Tocci

should rather be considered as uncontrolled hypertension, which may nevertheless lead to increased risk of major CV events related to hypertension. As indicated in the most recent hypertension guidelines, hypertension is defined as resistant (or refractory) to treatment when a therapeutic plan that consists of adherence to healthy lifestyle measures and the prescription of at least three drugs (including a diuretic) in adequate doses has failed to lower systolic and/or diastolic BP to goal, as defined by BP levels below 140/90mmHg in the general population of hypertensive patients and below 130/80mmHg in those hypertensive patients at high or very high global CV risk (e.g., diabetics) [68] . In this article, we will discuss epidemiological aspects of true resistant hypertension, and propose a diagnostic algorithm to properly identify and treat patients with this condition in clinical practice. Finally, we will address modern therapeutic approaches, including new pharmacological options and nonpharmacologic interventions, which may help to better control BP levels in patients with resistant forms of hypertension.
Epidemiology & clinical relevance of resistanthypertension

A poor control of BP level is a very common situation in clinical practice, as it has been described in international [1416] , regional [17] or clinical [18] settings. One of the most recent and largest analyses based on observational studies in hypertension conducted in Italy between 2000 and 2007 revealed that only 22% of approximately 53,000 hypertensive patients included in these surveys were under control, whereas 39% had BP levels exceeding 140/90mmHg and approximately one third (32.9%) had diastolic BP levels above 100mmHg. In addition, approximately 5% of patients, predominantly elderly individuals, had isolated systolic hypertension [18] . In a more specific project aimed at identifying the prevalence of resistant hypertension with automated ambulatory BP monitoring systems conducted in Spain, more than 1000 investigators, selected through primary care physicians and referral units, participated by including a cohort of approximately 52,000 patients with untreated hypertension or previously diagnosed hypertensive patients on pharmacological treatment [19] . Among these patients, more than 6000 were revealed to have resistant hypertension, since their BP levels were above 140/90mmHg, in spite of using more than three concomitant antihypertensive drugs from different classes, including diuretics (either thiazide or loop diuretics) [20] . Thus, the prevalence of resistant hypertension in this Spanish cohort was approximately 12%, with the remaining proportion of hypertensive patients having a satisfactory control of their BP levels [20] . The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) highlighted for the first time the potential impact of resistant hypertension among general practitioners [20] . In this large, interventional clinical trial performed in hypertensive patients with a high CV risk profile randomized to receive an antihypertensive treatment based on either a calcium channel blocker (CCB; amlodipine), a diuretic (chlorthalidone) or an ACE inhibitor (lisinopril), the percentages
812

of patients achieving the recommended BP targets were approximately 61, 57 and 54%, respectively. It should be highlighted, however, that in this trial approximately one-third of the patients were receiving three or more antihypertensive agents, and in spite of that their BP levels remained above normal values. The real prevalence of resistant hypertension in the clinical practice is, however, far from being definitely assessed. In fact, some physicians tend to classify those individuals in whom systolic and/or diastolic BP goals are difficult to achieve under multiple antihypertensive drug treatment as resistant hypertensive patients, and this may simply reflect a number of diagnostic problems that are not systematically addressed in routine practice, as well as the complexity of choosing the appropriate treatment in the individual hypertensive patient. Failure to achieve a satisfactory BP control often results in physicians disappointment and resignation to accept persistently elevated BP levels. Alternatively, an excessive number of patients are referred to hypertension centers, which are overwhelmed by this type of referral. In fact, only a minority of general practitioners or specialists operating in outpatient clinics adhere to the definition proposed by current guidelines [68] , and identify true resistant hypertension after all necessary diagnostic steps (including home BP evaluation and 24-h ambulatory BP monitoring, where appropriate) and therapeutic (pharmacological and nonpharmacological) measurements have been undertaken [21] . Thus, efforts should be devoted to clearly identify patients with true resistant hypertension, as defined previously [68] , and to distinguish them from those with uncontrolled or challenging forms of hypertension, since these latter patients may only require further diagnostic steps or therapeutic adjustments. This is of crucial relevance, especially to reduce the clinical inertia that may be based on the physicians erroneous assumption that the patient is resistant to treatment. As an example supporting this view, in the Reassessment of Antihypertensive Chronic Therapy (REACT) study, 42% of physicians decided not to modify the antihypertensive regimen, even though their hypertensive patients were not controlled after more than 1year of follow-up [22] . This issue remains, in our opinion, a major problem in the clinical management of hypertension. A closer look into major pathophysiological aspects, diagnostic options and available therapeutic interventions for treating this condition may be of help when managing patients with resistant hypertension.
Pathophysiological & clinical aspects
Pseudo-resistant hypertension

The diagnosis of resistant hypertension should begin with an initial fundamental clinical step, which is the identification of pseudo-resistant hypertension. This condition, which is frequently confused with resistant hypertension, is characterized by BP levels persistently above normal values at clinic measurements in patients who do not have resistant hypertension[68] . Several factors may contribute to maintain elevated BP levels and induce the perception of resistant hypertension. The identification and removal of these factors may contribute to normalize BP levels and, thus, to rule out the diagnosis of resistant hypertension.
Expert Rev. Cardiovasc. Ther. 8(6), (2010)

How to diagnose & treat resistant hypertension in daily clinical practice

Review

Box1 reports a number of potential causes that might be involved that primary aldosteronism accounts for up to 20% of resistant in the genesis of pseudo-resistant hypertension. Among these hypertension [34,38,39] . It should be noted that this population was causes, inaccurate BP measurements [23] or the use of inadequate mostly recruited among hypertensive patients with BP levels above dosages or inappropriate combinations of drugs [24] probably rep- 140/90mmHg, despite a drug regimen of three antihypertensive resent the most common. White-coat hypertension may represent drugs, including a diuretic [27] . another possible cause of pseudo-resistant hypertension, which Lack of sleep or sleep apnea syndrome, which represent growneeds to be properly identified [25] . The prognostic significance ing problems in modern society, have recently been proposed as of this condition, however, is still debated. Some authors have emerging causes of moderate-to-severe forms of hypertension, reported that patients with white-coat hypertension may develop including masked hypertension (e.g., elevated BP levels at home sustained forms of hypertension over the years [26] . and normal office BP levels) [40] and resistant hypertension [39] . In this latter regard, studies published in the last few years have shown that the presence of true resistant hypertension in cohorts Drug-induced hypertension of hypertensive patients has been better defined by using 24-h Another aspect that should be considered when excluding potenambulatory BP monitoring, which can also be of help in character- tial causes of poor BP control in the presence of multiple and izing the BP profile of this clinical condition. In a study published appropriate antihypertensive therapy is drug-induced hyperby Veglio etal. in 2001, the use of ambulatory BP monitoring tension [41] . A list of drugs potentially involved in the genesis allowed the detection of the presence of true resistant hyperten- and maintenance of resistant hypertension is reported in Box2 . sion in approximately 2% of the overall hypertensive outpatients Among these, NSAIDs (e.g., cyclooxygenase-2 inhibitors) and referred to that hypertension unit [27] . In this subgroup, patients sympathomimetic agents, including anorectics, appear to be with true resistant hypertension were significantly younger, and the most frequent causes of drug-induced sustained BP elevahad significantly higher sodium and alcohol intake than those tion. Abuse of cocaine, amphetamines and other illicit drugs, recorded in patients with white-coat resistant hypertension [25] . as well as oral contraceptive hormones, also represent emergAnother analysis performed by Brown etal. in 2001 substan- ing problems. Other potential substances that may render the tially confirmed the use of 24-h ambulatory BP monitoring as an treatment of hypertension more difficult include herbal princiappropriate step to be undertaken before further investigating or ples, energizing drinks, androgens and anabolizing hormones. treating patients with apparently resistant hypertension [28] . Box1. Potential causes of pseudo-resistant hypertension.

Secondary hypertension

An important diagnostic step is to exclude a secondary cause of hypertension [29] . Among the potential causes of impaired or insufficient response to multiple antihypertensive drug therapy, renal parenchimal disease [30,31] , renal artery disease [32,33] and hyperaldosteronism [34,35] may be viewed as the most frequently reported in large observational databases. The estimated prevalence of these conditions, however, varies between 1.8% for renal parenchimal disease, 3.4% for renal artery disease and 8% (range: 513%) for hyperaldosteronism according to an analysis published in 2006 by Moser and colleagues [36] . Indeed, the presence of primary hyperaldosteronism should be always considered in patients who have developed a challenging form of hypertension [37] . In a study by Veglio and colleagues performed in 2001 in a population of more than 1500patients with so-called resistant hypertension, it was found that 11.3% of these patients had, indeed, primary hyperaldosteronism [27] . Other studies report
www.expert-reviews.com

Factors related to the physician Improper blood pressure measurement Use of inappropriate antihypertensive medication Inadequate dosages Inappropriate combinations Physician inertia (failure to change or increase dose regimens when not at goal blood pressure) Poor communication between doctor and patient Complicated therapeutic plan (especially in the presence of multiple concomitant medications) or complicated dosing schedules of antihypertensive drugs Factors related to the patient White-coat effect Drug-related side effects Low commitment Inadequate patient education Concomitant use of oral contraceptives Concomitant use of anti-inflammatory or sympathomimetic agents Chronic use of steroids Memory or psychiatric problems and cognitive disorders (elderly subjects) Cost of medication (in some healthcare systems) Other causes Obstructive sleep apnea syndrome Chronic kidney disease Primary or secondary hyperaldosteronism Severe atherosclerotic disease (calcification) of the arterial wall (elderly subjects) Aortic valve sclerosis with hemodynamically significant insufficiency

813

Review

Volpe & Tocci

Finally, immunosuppressant agents, which are commonly used in patients undergoing organ transplantation or suffering from immune diseases, should be considered as potential causes of resistant hypertension. The mechanisms by which the different drugs may induce a persistent rise in BP levels are multiple and not fully elucidated, sharing several common pathways that are schematically reported in Figure1. In particular, three major pathophysiological mechanisms have been advocated. They include: Increased vascular tone Salt and water retention with volume expansion Abnormal activation of the sympathetic nervous system or reninangiotensin system In addition, an imbalance between nitric oxide production and vasoconstricting agents at the endothelial level may be involved in the pathogenesis of these situations. In some circumstances, such as the use of cyclosporine, the increase in renin production also appears to play a major role.

On the basis of these considerations, the importance of an accurate collection of patients personal clinical history appears to be a fundamental step for identifying any potential cause of resistant hypertension, especially when this has not been taken into sufficient account in previous visits. Thus, even in patients not responding to three or more antihypertensive drugs, an accurate collection of information on drug consumption or alcohol abuse may be extremely important.
Difficult control of blood pressure in specific clinicalconditions

Patients clinical characteristics associated with the presence of resistant hypertension include older age (increased arterial stiffness), baseline BP levels in the upper range (grade23 hypertension) at diagnosis, obesity, excessive dietary salt ingestion, black race, female gender and residence in specific geographical areas. In particular, with regard to the presence of obesity, any effort should be undertaken to properly control it, as well as any other potentially modifiable risk factor, in order to better manage high BP levels.

NSAIDs

Glucocorticoids and mineralocorticoids

Cyclosporin

Erythropoiesisstimulating agents

Illicit substance abuse

Reduced production of PGI2

Oxidative stress (reduced NO bioavailability)

Reduced hypoxiamediated vasodilation

Reduced renal blood flow

Vasoconstriction Glomerular ischemia

Increased vascular tone Systemic vasoconstriction

Increased plasma renin concentration Increased plasma renin activity

Endothelial dysfunction

Salt and water retention

RAS activation

CNS activation

Sustained BP elevation

Figure1. Pathophysiological mechanisms involved in the genesis of drug-induced arterial hypertension. BP: Blood pressure; NO: Nitric oxide; RAS: Reninangiotensin system.

814

Expert Rev. Cardiovasc. Ther. 8(6), (2010)

How to diagnose & treat resistant hypertension in daily clinical practice

Review

Other clinical conditions can be found in patients with resistant hypertension. These include severe left ventricular hypertrophy, cardiomyopathies, diabetes mellitus with proteinuria, and chronic kidney disease. Finally, aortosclerosis and insufficiency of the aortic valve are frequently associated with forms of isolated systolic hypertension, which may not benefit an aggressive antihypertensive drug therapy.
Therapeutic approach to resistant hypertension

Box2. Potential upcoming options for treating resistant hypertension.

Direct renin inhibitors (aliskiren) NEP inhibitors (omapatrilat compassionate use) New aldosterone antagonists (eplerenone and others) Aldosterone synthase inhibitors Clonidine extended release Endothelin antagonists Novel combination algorithms
NEP: Neutral endopeptidase.

With regard to the therapeutic approach to resistant hypertension, besides the appropriate use of the five major classes of antihypertensive drugs in combination, as recommended by the current European and North-American guidelines, new therapeutic options are becoming available (Box 2) [68] . It must be highlighted, however, that appropriate lifestyle interventions, such as salt restriction, weight loss, physical activity, smoking cessation and alcohol abstention, should be always considered in any therapeutic plan aimed at reducing BP levels to goal. Accumulating evidence, in fact, supports the role of these interventions in improving BP control and reducing the incidence of major CV events in high-risk hypertensive patients. Thus, they must be viewed as a fundamental step when treating patients with either essential or resistant hypertension.
Aldosterone antagonists & potassium-sparing diuretics

sleep apnea syndrome in patients with resistant hypertension, although an increase in serum creatinine levels and plasma renin activity has been reported [49] . Finally, it should be mentioned that sometimes (thiazide or loop) diuretics are underused or underdosed in the treatment of difficult forms of hypertension owing to clinical inertia or fear of the side effects. One of the common features of patients with resistant hypertension may be the presence of subclinical hypervolemia, which should be carefully considered in each patient with persistently elevated BP levels.
Combination therapy

Aldosterone antagonists represent a well-established pharmacological tool for managing patients with resistant hypertension, even when true hyperaldosteronism is difficult to identify clinically or after performing sophisticated investigations. Besides the established use of these drugs, which have proven to be effective in previous clinical trials [42,43] , eplerenone, canrenone and potassium canreonate may represent alternatives for treating resistant hypertension, in view of the lesser incidence of drug-related side effects (e.g., gynecomastia) [44,45] . Amiloride may represent another potential option [46] , although the efficacy of this compound is controversial in treating patients with resistant hypertension [43] . It should be also highlighted, however, that some of these compounds (mostly canrenone and potassium canreonate) are not available in all countries. A recent analysis of the results of the AngloScandinavian Cardiac Outcomes TrialBlood Pressure Lowering Arm (ASCOTBPLA) has adopted an antihypertensive treatment algorithm to control resistant hypertension in both the amlodipineand atenolol-based regimen using the a-blocker doxazosin or other antihypertensive drugs, mostly spironolactone [47] . In this population, the use of spironolactone was able to reduce BP in those patients who were not responding to multiple drug combinations. This therapeutic approach reduced systolic BP levels from 156.9/85.3 to 135.1/75.8mmHg [47] . In another study by Nishizaka looking at the effect of spironolactone, the average reduction in systolic and diastolic BP levels in patients with resistant hypertension was approximately 25mmHg after 6months [48] . More recently, preliminary evidence has demonstrated that treatment with spironolactone significantly reduces ambulatory and clinic BP levels, and ameliorates the severity of obstructive
www.expert-reviews.com

Clinical studies have revealed that an effective way to control resistant hypertension can be based on an early initiation of antihypertensive treatment with two-drug combinations, as suggested by current guidelines [68] . Combination strategy should be based on the use of drugs with synergistic mechanisms. Available evidence demonstrated a better BP control by combining drugs able to modulate the abnormal activation of the reninangiotensin system, including ACE inhibitors or ARBs, with vasodilating agents, such as CCBs [5052] , a-blockers [53,54] or diuretic (thiazide) drugs[55,56] . In this latter regard, it should be mentioned that in the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial [57] , only one-third of high-risk hypertensive patients were under control on routine antihypertensive therapy at the beginning of the study, while more than 80% were under control with both study drug combination regimens, including an ACE inhibitor and either a CCB or a thiazide diuretic at the end of the study. Interesting results have been obtained with the ARB olmesartan medoxomil combined with either the CCB amlodipine or a thiazide diuretic, or both [50,51] , or with the ACE inhibitor enalapril combined with the CCB lercanidipine [58] . In these clinical studies the percentage of responders in difficult-to-treat patients was up to 8090%, which is a very encouraging result [50,51,58] .
Direct renin inhibition

Among the potential new pharmacological options, the use of the direct renin inhibitor, aliskiren, has been revealed to be effective in patients who are not under control on multiple antihypertensive drug therapy, including other drugs blocking the renin angiotensin system [59,60] . No specific study has been performed with aliskiren in patients with resistant hypertension, although
815

Review

Volpe & Tocci

this would be highly recommended. At this time, aliskiren may only be considered as a promising option in this clinical setting. Preliminary analysis, performed in a large observational database of prescriptions collected in the real world of clinical practice in Italy, showed a high rate of responders among hypertensive patients with resistant or challenging hypertension, who were already treated with at least three antihypertensive drugs [101] .
Novel antihypertensive agents

Among potentially novel antihypertensive agents, darusentan, a specific endothelin antagonist, has recently been tested in a randomized clinical trial performed in hypertensive patients with established diagnosis of resistant hypertension [65] . Although the results of this study demonstrated that this strategy may provide additional reduction in BP levels in patients who did not attain their treatment goals with three or more antihypertensive drugs [65] , the future inclusion of this drug in the therapeutic armamentarium of hypertension is still under debate.
Nonpharmacological agents

Aldosterone synthase inhibitors are currently being tested as an option to treat resistant hypertension [61] . Other potential effective tools include a new formulation of clonidine with extended release, endothelin antagonists and neutral endopeptidase inhibitors, particularly omapatrilat. This compound has not been admitted for hypertension treatment, owing to side effects observed in specific populations, although it could be reconsidered in the future for compassionate use in patients with resistant hypertension [6264] .

Several nonpharmacologic therapeutic approaches to treat patients with resistant hypertension are under development or evaluation. Among these, preliminary data have recently demonstrated the efficacy, safety and tolerability of implantable pulse generators in both experimental and human studies [66] . This system consists of a surgically and chronically implanted pulse

How to properly diagnose resistant hypertension BP >140/90 mmHg in hypertensive patients receiving at least three antihypertensive drugs, including a diuretic, as adequate (full) doses

Check any discrepancies among office, home and 24-h ambulatory BP measurements

Normal home and high clinic and ambulatory BP levels: office-resistant hypertension

All BP above limits Check patients adherence to antihypertensive drug prescriptions

Normal home, ambulatory and high clinic BP levels: pseudo-resistant hypertension

Check patients assumption of any interfering drug or substance

Identify and treat possible causes of secondary hypertension and any concomitant condition that may persistently keep BP levels elevated

Optimize and titrate pharmacologic and nonpharmacologic therapies

Refer patient to hypertension center

Figure2. How to properly diagnose true resistant hypertension in daily clinical practice. Diagnose and treat any concomitant conditions that may affect high blood pressure levels, including: renal parenchimal disease, renovascular disease, aldosteronism, thyroid disease, Cushings syndrome, pheocromocytoma, aortic coarctation, severe aortic atherosclerosis (aortosclerosis) and sleep apnea syndrome. BP: Blood pressure.

816

Expert Rev. Cardiovasc. Ther. 8(6), (2010)

How to diagnose & treat resistant hypertension in daily clinical practice

Review

generator and bilateral perivascular carotid sinus leads, and is being evaluated in prospective clinical trials for the treatment of drug-resistant hypertension [66] . Pilot studies support the efficacy of renal artery denervation in treating patients with true resistant hypertension, in which a renal origin of the disease has been established [67,68] . Furthermore, neurovascular decompensation has recently been evaluated as a potential treatment option in patients with uncontrolled or true resistant hypertension, although recent studies indicate it may only be useful temporarily [69] . As well as for the implantation of carotid pulse generators, it should be highlighted, however, that these procedures are invasive and irreversible, and that nowadays they should be strictly recommended to those patients with uncontrolled BP levels despite optimal pharmacological strategy, following a rigorous clinical evaluation of the patient, the exclusion of any reasonable alternative and a presumably unfavorable prognosis of the disease.
Expert commentary

Worldwide prevalence of hypertension is high and increasing, and BP control in hypertensive populations remains unacceptably poor. This has dramatic consequences for public health, because the benefit of antihypertensive treatment is mostly related to the degree of systolic or diastolic BP reduction. The situation is even more dramatic in perspective owing to the continuing rise in the prevalence of hypertension and other comorbidities at a global level. The lack of BP control may be related to several factors, including doctors inertia, patients poor compliance, insufficient patient doctor communication, inappropriate measurements of BP, or inadequate or insufficient antihypertensive interventions. The diagnosis of resistant hypertension is often advocated as a major cause. Key issues

Although the diagnosis of resistant hypertension is very common in the clinical practice, it is often used to improperly define patients with difficult or challenging forms of hypertension. According to current guidelines, the definition of resistance (or refractory) to treatment should be limited to those hypertensive patients in whom adherence to lifestyle measures and prescription of at least three drugs (including a diuretic) in adequate doses has failed to lower systolic and/or diastolic BP to goal [68] . Correct diagnosis and management of resistant hypertension is a fundamental step when approaching patients with difficult-to-treat or challenging hypertension, and it should be carried out in careful, mandatory clinical steps as schematically shown in Figure2. First, it is important to consider the diagnosis of pseudo-resistant hypertension and hypertension related to concomitant diseases, use of drugs or other substances, and secondary hypertension. The treatment of resistant hypertension should include optimization of dosages and more frequent use of rational combination therapy in order to increase the synergistic effects on BP lowering. Novel pharmacological and nonpharmacological interventions can be considered as alternative options to treat patients with resistant hypertension.
Five-year view

Over the last few decades, control of BP levels has been poorly achieved in worldwide general practice. Resistant hypertension has represented a major factor contributing to the lack of BP control. Beside the appropriate use of appropriate lifestyle interventions and the use of five major classes of antihypertensive drugs in rational combination strategies, new therapeutic options are becoming available. They mostly include drugs able to counteract the deleterious effects of abnormal activation of the reninangiotensin system or the sympathetic nervous system at different levels than previously adopted (e.g., renin or prorenin inhibition, aldosterone

Arterial hypertension is a complex disease associated with an increased risk of cardiovascular and renal morbidity and mortality. Blood pressure-lowering therapy significantly reduces the burden of hypertension-related disease and incidence of major cardiovascular and renal outcomes. In spite of progressive and significant progress in diagnostic options and therapeutic interventions, blood pressure control is poorly achieved in global general practice. Uncontrolled blood pressure levels further increase the risk of developing major cardiovascular and renal events in treated hypertensivepatients. In clinical practice, the diagnosis of resistant hypertension is very common, and it is often used to improperly define patients with difficult or challenging forms of hypertension. Hypertension is properly defined as resistant (or refractory) to treatment when a therapeutic plan that consists of adherence to healthy lifestyle measures and the prescription of at least three drugs (including a diuretic) in adequate doses has failed to lower systolic and/or diastolic blood pressure to goal, as defined by blood pressure levels below 140/90mmHg in the general population of hypertensive patients and below 130/80mmHg in those hypertensive patients at high or very global cardiovascular risk. Prevalence and clinical aspects of this clinical condition are not fully elucidated, although it has been clearly associated with a significantly increased risk of cardiovascular morbidity and mortality. Correct diagnosis is a fundamental step for the clinical management of resistant hypertension. Combination therapy based on drugs belonging to different antihypertensive drug classes with synergistic blood pressure-lowering effects is often required in this clinical setting. Novel pharmacologic and nonpharmacologic options, besides the appropriate use of the major classes of antihypertensive drugs (mostly in combination strategies), are becoming available or are under evaluation in patients with resistant hypertension, for improving blood pressure control.

www.expert-reviews.com

817

Review

Volpe & Tocci

synthase inhibitors, and so on), or novel combination strategies. In addition, nonpharmacological tools, such as carotid implantable pulse generators, renal artery denervation and neurovascular decompensation, will soon become available for treating patients with uncontrolled BP levels or resistant hypertension. Preliminary data from clinical trials showed promising results of these additional strategies in terms of BP-lowering efficacy and increasing responders rates to antihypertensive strategies. Further research and clinical studies are needed in order to better clarify the main pathophysiological aspects and optimal therapeutic approaches to be applied in patients with resistant hypertension.
References
Papers of special note have been highlighted as: of interest of considerable interest
1

Financial & competing interests disclosure

Massimo Volpe has received research grants and has been a speaker in several symposia sponsored by pharmacological companies producing antihyper tensive agents; he has served on the international advisory boards of Merck Sharpe & Dohme, Sanofi-Aventis/Bristol Myers Squibb, Bayer Schering Pharma, Novartis Pharma, Boehringer Ingelheim, Pfizer and Daichii Sankyo. The authors have no other relevant affiliations or financial involve ment with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Overview of the main pathophysiologic aspects, diagnostic options and therapeutic intervention of resistanthypertension.
13

Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet 361(9369), 16291641 (2003). Kearney PM, Whelton M, Reynolds K etal. Global burden of hypertension: analysis of worldwide data. Lancet 365(9455), 217223 (2005). Turnbull F. Effects of different bloodpressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362(9395), 15271535 (2003). Among major drug classes of antihypertensive agents, no significant differences are found in terms of blood pressure (BP)-lowering efficacy; thus, the main benefit of antihypertensive treatment is BP reduction perse. Turnbull F, Neal B, Algert C etal. Effects of different blood pressurelowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med . 165(12), 14101419 (2005). Kotseva K, Wood D, De Backer G etal. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373(9667), 929940 (2009). The results of this European survey show a persistently high prevalence of major cardiovascular risk factors in the general population of different countries. Mancia G, De Backer G, Dominiczak A etal. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force

for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J.Hypertens. 25(6), 11051187 (2007).
7

Lenfant C, Chobanian AV, Jones DW, Roccella EJ. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension 41(6), 11781179 (2003). Williams B, Poulter NR, Brown MJ etal. British Hypertension Society guidelines for hypertension management 2004 (BHSIV): summary. Br. Med.J. 328(7440), 634640 (2004). Palmer BF. Improving BP control with combined reninangiotensin system blockade and thiazide diuretics in hypertensive patients with diabetes mellitus or kidney disease. Am. J.Cardiovasc. Drugs 8(1), 914 (2008). Struijker-Boudier HA, Ambrosioni E, Holzgreve H etal. The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbiditymortality trials? Int. J.Clin. Pract. 61(9), 15921602 (2007). Combination therapy based on the use of multiple, concomitant antihypertensive drug classes is often needed in managing hypertensive patients in order to achieve the recommended BP goals. Wolf-Maier K, Cooper RS, Banegas JR etal. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 289(18), 23632369 (2003). Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J.Am. Coll. Cardiol. 52(22), 17491757 (2008).
14

Calhoun DA, Jones D, Textor S etal. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51(6), 14031419 (2008). Whyte JL, Lapuerta P, LItalien GJ, Franklin SS. The challenge of controlling systolic blood pressure: data from the National Health and Nutrition Examination Survey (NHANES III), 19881994. J.Clin. Hypertens. (Greenwich ) 3(4), 211216 (2001). Wolf-Maier K, Cooper RS, Kramer H etal. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 43(1), 1017 (2004). Cooper RS, Wolf-Maier K, Luke A etal. An international comparative study of blood pressure in populations of European vs. African descent. BMC Med. 3, 2 (2005). Boersma E, Keil U, De Bacquer D etal. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J.Hypertens. 21(10), 18311840 (2003). Volpe M, Tocci G, Trimarco B etal. Blood pressure control in Italy: results of recent surveys on hypertension. J.Hypertens. 25(7), 14911498 (2007). Gorostidi M, Sobrino J, Segura J etal. Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20,000-patient database in Spain. J.Hypertens. 25(5), 977984 (2007).
Expert Rev. Cardiovasc. Ther. 8(6), (2010)

15

10

16

17

18

11

19

12

818

How to diagnose & treat resistant hypertension in daily clinical practice

Review

20

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23), 29812997 (2002). Tocci G, Giovannelli F, Sciarretta S etal. Management of hypertension and stroke prevention: results of the Italian cardiologist survey. Int. J.Clin. Pract. 63(2), 207216 (2009). Volpe M, Notaro LA, Tocci G etal. The Reassessment of Antihypertensive Chronic Therapy (REACT) Study: an Italian observational study on hypertension management in patients with established therapy. High Blood Pressure & Cardiovascular Prevention 11(4), 175185 (2004). Mancia G, Parati G, Pomidossi G etal. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 9(2), 209215 (1987). Borghi C, Dormi A, DAddato S, Gaddi A, Ambrosioni E. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J.Hypertens. 22(9), 17071716 (2004). Verdecchia P, Staessen JA, White WB, Imai Y, OBrien ET. Properly defining white coat hypertension. Eur. HeartJ. 23(2), 106109 (2002). Mancia G, Bombelli M, Facchetti R etal. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 54(2), 226232 (2009). Veglio F, Rabbia F, Riva P etal. Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension. Clin. Exp. Hypertens. 23(3), 203211 (2001). Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am. J.Hypertens. 14(12), 12631269 (2001). Rossi GP, Seccia TM, Pessina AC. Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit. Rev. Clin. Lab. Sci. 44(1), 185 (2007). Locatelli F, Manzoni C, Marcelli D. Treatment of hypertension in chronic renal insufficiency. J.Nephrol. 10(4), 220223 (1997).

31

Fournier A, el Esper N, Makdassi R etal. Hypertension and progression of renal insufficiency. Nephrol. Dial. Transplant. 9(Suppl.3), 2834 (1994). London GM, Guerin AP, Pannier B, Marchais SJ, Safar ME. Large artery structure and function in hypertension and end-stage renal disease. J.Hypertens. 16(12Pt2), 19311938 (1998). Brown MA, Whitworth JA. Hypertension in human renal disease. J.Hypertens. 10(8), 701712 (1992). Gonzaga CC, Calhoun DA. Resistant hypertension and hyperaldosteronism. Curr. Hypertens. Rep. 10(6), 496503 (2008). Chun TY, Pratt JH. Hyperaldosteronism: acommonly occurring underlying feature of essential hypertension and the metabolic syndrome? Curr. Opin. Endocrinol. Diabetes Obes. 14(3), 210212 (2007). Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N.Engl. J.Med. 355(4), 385392 (2006). Douma S, Petidis K, Doumas M etal. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 371(9628), 19211926 (2008). Kittisupamongkol W. Secondary causes of resistant hypertension. Arch. Intern. Med . 169(7), 717 (2009). Pimenta E, Calhoun DA, Oparil S. Sleep apnea, aldosterone, and resistant hypertension. Prog. Cardiovasc. Dis. 51(5), 371380 (2009). Overview of the main pharmacological aspects and potential clinical and therapeutic implications of antihypertensive treatment based on the direct renin inhibitor, aliskiren. Baguet JP, Levy P, Barone-Rochette G etal. Masked hypertension in obstructive sleep apnea syndrome. J.Hypertens. 26(5), 885892 (2008). de Leeuw PW, Gaillard CA, Birkenhager WH. Drug-induced hypertension. Neth. J.Med. 43(Suppl.1), S39S43 (1993). Berecek KH, Farag A, Bahtiyar G, Rothman J, McFarlane SI. Adding low-dose spironolactone to multidrug regimens for resistant hypertension. Curr. Hypertens. Rep. 6(3), 211212 (2004). Lane DA, Beevers DG. Amiloride 10 mg is less effective than spironolactone 25 mg in patients with hypertension resistant to a

multidrug regime including an angiotensin-blocking agent. J.Hypertens. 25(12), 25152516 (2007).

44

32

George J, Struthers AD. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. Expert Opin. Pharmacother. 8(17), 30533059 (2007). Antonio Costa J, Rodilla E, Perez-Lahiguera F, Maria Pascual J. Eplerenone in resistant hypertension with previous spironolactone intolerance. Med. Clin. (Barc.) 132(19), 756757 (2009). Hood SJ, Taylor KP, Ashby MJ, Brown MJ. The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosteronerenin ratio. Circulation 116(3), 268275 (2007). Chapman N, Dobson J, Wilson S etal. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49(4), 839845 (2007). Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J.Hypertens. 16(11 Pt 1), 925930 (2003).

45

21

33

34

46

22

35

47

36

23

37

48

24

38

25

39

Stepped-care combination strategy based on ARBs, dihydropyridine calcium channel blockers and thiazide diuretics improve BP control significantly more than monotherapy.
49

26

Gaddam K, Pimenta E, Thomas SJ etal. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J.Hum. Hypertens. DOI:10.1038/ jhh.2009.96 (2009) (Epub ahead of print).

27

40

Combination strategy based on ARBs and dihydropyridine calcium channel blockers significantly improves BP control more than monotherapy.
50

28

41

29

Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin. Drug Investig. 29(6), 381391 (2009). Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin. Drug Investig. 29(1), 1125 (2009).

42

51

30

43

www.expert-reviews.com

819

Review
52

Volpe & Tocci

Brachmann J, Ansari A, Mahla G, Handrock R, Klebs S. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv. Ther. 25(5), 399411 (2008). Calo LA, Bertipaglia L, Pagnin E etal. Effect of doxazosin on oxidative stress related proteins in essential hypertensive patients. Clin. Exp. Hypertens. 28(2), 181188 (2006). Pessina AC, Ciccariello L, Perrone F etal. Clinical efficacy and tolerability of a-blocker doxazosin as add-on therapy inpatients with hypertension and impairedglucose metabolism. Nutr. Metab.Cardiovasc. Dis. 16(2), 137147 (2006). Campo C, Segura J, Roldan C etal. Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertension. Blood Press. Suppl. 2, 1621 (2003).

57

Jamerson K, Weber MA, Bakris GL etal. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N.Engl. J.Med. 359(23), 24172428 (2008). Tocci G, Palano F, Pagannone E etal. Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine. Expert Rev. Cardiovasc. Ther. 7(2), 115123 (2009). Volpe M. Cardiovascular risk in hypertension can we ask for more?: Focus on aliskiren. High Blood Pressure & Cardiovascular Prevention 15(4), 255268 (2008). Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs 67(12), 17671792 (2007). Bureik M, Hubel K, Dragan CA etal. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11b -hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension. Mol. Cell. Endocrinol. 217(12), 249254 (2004). Tikkanen T, Tikkanen I, Rockell MD etal.Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Hypertension 32(4), 778785 (1998). Trippodo NC, Robl JA, Asaad MM etal. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS182657 in experimental hypertension and heart failure. J.Pharmacol. Exp. Ther. 275(2), 745752 (1995).

64

French JF, Anderson BA, Downs TR, DageRC. Dual inhibition of angiotensinconverting enzyme and neutral endopeptidase in rats with hypertension. J.Cardiovasc. Pharmacol. 26(1), 107113 (1995). Weber MA, Black H, Bakris G etal. Aselective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebocontrolled trial. Lancet 374(9699), 14231431 (2009). Young KC, Teeters JC, Benesch CG, Bisognano JD, Illig KA. Costeffectiveness of treating resistant hypertension with an implantable carotid body stimulator. J.Clin. Hypertens. (Greenwich ) 11(10), 555563 (2009). Krum H, Schlaich M, Whitbourn R etal. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373(9671), 12751281 (2009). Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympatheticnerve ablation for uncontrolled hypertension. N.Engl. J.Med. 361(9), 932934 (2009). Frank H, Heusser K, Geiger H etal. Temporary reduction of blood pressure and sympathetic nerve activity in hypertensive patients after microvascular decompression. Stroke 40(1), 4751 (2009).

58

65

53

59

66

54

60

67

55

61

68

From the beginning of the study, a combination strategy based on an ACE inhibitor and dihydropyridine calcium channel blocker reduced the risk of cardiovascular morbidity and mortality significantly more than a combination based on ACE inhibitor and thiazide diuretic in high-risk hypertensive patients, beyond the BPloweringefficacy.
56

62

69

Oparil S, Barr E, Elkins M etal. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin.Ther. 18(4), 608625 (1996).

63

Website
101

National registry of cardiovascular drugs in Italy. An analysis of Agenzia Italiana del Farmaco (AIFA) observational database http://cardiologici.agenziafarmaco.it/ (Accessed 8 January 2010)

820

Expert Rev. Cardiovasc. Ther. 8(6), (2010)